Some factors affecting the decision on non-mandatory vaccination in an influenza pandemic: comparison of pandemic (H1N1) and seasonal influenza vaccination
Background: The 2009 influenza pandemic caused by the influenza A (H1N1) 2009 virus was accompanied by a debate about whether or not to be vaccinated. The percentage of people who decided to be vaccinated was lower than in the case of seasonal influenza vaccination. We therefore compared factors influencing the decision on pandemic and seasonal influenza vaccination.
Method: Slovene inhabitants aged 18 and over (N=1383) completed an internet based survey on socio-demographic and health behaviour-related characteristics, personality traits, and characteristics of decision-making. Two stepwise logistic regression analyses were performed, one with an uptake of the pandemic influenza vaccine and the other with an uptake of the seasonal influenza vaccine as a dependent variable.
Results: In addition to common predictors of a decision in favour of the two vaccinations (age, gender, chronic illnesses, working in healthcare, trust in media news and vaccination side-effects in someone close), deciding in favour of vaccination against the pandemic virus was related to living with children and thoroughness in decision-making. It was also related to being vaccinated against seasonal influenza, trust in pandemic vaccine safety and professional information in favour of vaccination, and the decision of someone close.
Conclusions: In the face of the pandemic threat and lack of information, people behaved as they had in previous similar situations and according to the behaviour of people close to them and information from trusted sources. Concern for children and decision-making characteristics also became important. These factors should be considered in future crisis interventions.
;10:531-4. 6. Salmon DA, Proschan M, Forshee R, Gargiullo P, Bleser W, Burwen DR, et al. Association between Guillain-Barré syndrome and influenzaA (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet. 2013;381:1461-8. 7. Launay E, Ovetchkine P, Saint-Jean M, Coïc L, Ducruet T, Charest H, et al. Novel influenza A (H1N1): clinical features of pediatric hospitalizations in two successive waves. Int J Infect Dis. 2011;15: e122. 8. Lapinsky SE. H1N1 novel influenza A in pregnant and immuno-compromised patients. Crit Care Med. 2010;38:e52. 9. Baz M
., Harrower B., Wong F.J.K.: Transmission of influenzaA(H1N1) 2009 pandemic viruses in Australian swine. Influenza Other Resp Viruses 2012, 6 , 42-47. 8. Ducatez M.F., Sonnberg S., Hall R.J., Peacey M., Ralston J., Webby R.J., Huang O.S.: Genotyping assay for the identification of 2009-2010 pandemic and seasonal H1N1 influenza virus reassortants. J Virol Methods 2010, 168 , 78-81. 9. Grøntvedt C.A., Er C., Gjerset B., Germundsson A., Framstad T., Brun E., Jørgensen A., Lium B.: Clinical impact of infection with pandemic influenza (H1N1) 2009 virus in naive nucleus and
swine between 2009 and 2013. J Virol 2015, 89 (19): 9920-9931. 30. Galiano M, Agapow PM, Thompson C, Platt S, Underwood A, Ellis J, Myers R, Green J, Zambon M: Evolutionary pathways of the pandemic influenzaA (H1N1) 2009 in the UK. PLoS ONE 2011, 6(8): e23779. doi:10.1371/journal.pone.0023779 31. Sriwilaijaroen N, Suzuki Y: Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad 2012, B 88: 226-249. 32. Ward CW, Dopheide TA: Amino acid sequence and oligosaccharide distribution of the haemagglutinin from an early Hong Kong
distress syndrome. Am J Respir Crit Care Med 2011; 183: 1200–6. Brun-Buisson C Richard JC Mercat A Thiébaut AC Brochard L; REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome Am J Respir Crit Care Med 2011 183 1200 – 6 25 Kim SH, Hong SB, Yun SC, Choi WI, Ahn JJ, Lee YJ, et al Corticosteroid treatment in critically ill patients with pandemic influenzaA/H1N12009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183: 1207–14. Kim SH Hong SB Yun SC
response to influenzaA (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011;118:6769–6771. Yri OE Torfoss D Hungnes O Rituximab blocks protective serologic response to influenzaA (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment Blood 2011 118 6769 6771  Ide Y, Imamura Y, Ohfuji S, et al. Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies. Hum Vaccin Immunother 2014;10:2387–2394. 25424946 10.4161/hv.29094 Ide Y Imamura Y Ohfuji S